In recent years, the concept of “chronic hepatitis B requires antiviral therapy” has been gradually accepted by doctors and patients. At the same time, there are some doubts. How to choose antiviral drugs? How long do I need to adhere to them? How effective are they? What are the adverse effects? Will the disease recur after stopping the medication? These questions are always of great concern and interest to hepatitis B patients. The author summarizes the irregular antiviral situation of patients and finds that there are three misconceptions in the understanding of patients. One is the belief that antiviral requires lifelong medication. Many hepatitis B patients believe that hepatitis B, like hypertension and diabetes, requires lifelong medication. This misconception is very influential. Many patients see antiviral treatment as a “point of no return” and are hesitant about antiviral treatment. This has delayed the timing of treatment. The 2010 Chinese Guidelines for the Prevention and Treatment of Hepatitis B suggest a time point for discontinuation of antiviral therapy. Optimal: HBVDNA negative, HBsAg negative, time to 2.5 years. Ideal: e antigen-positive patients achieve ‘double attainment’ after treatment, HBVDNA negative, HBeAg negative, HbeAb positive, and treatment time up to 2.5 years. Effective: HBVDNA negative, 2.5 years of treatment for “major triplet” and 3 years for “minor triplet”. The second is the belief that the sooner you stop taking your medication, the better. Many patients are determined to fight a “constant battle” with the hepatitis B virus. However, there is a lack of scientific understanding of how long this battle should last. Some patients, after a few months of antiviral treatment, the viral indicators have improved significantly, hoping to see a good end and stop the drug sooner. Other patients who have been on medication for a few months but whose viral indicators have not reached the expected goal of turning negative, stop treatment immediately because they think it is ineffective. Anti-hepatitis B virus treatment must be patient and confident. “The current antiviral drugs are more expensive for one thing, in addition to may be accompanied by the prolongation of medication back to produce resistance and some adverse reactions. So, in all respects, of course it is good to be able to stop the medication as early as possible, but only if you complete a sufficient course of treatment to achieve the intended treatment goals.” The treatment of anti-hepatitis B virus is indeed a veritable “long war”. Hepatitis B patients are advised not to believe in false advertising. The first is to believe in the propaganda of the so-called quick turnaround of the hepatitis B virus. Thirdly, it is believed that all antiviral treatment can achieve the desired goal. Some patients complain why some people are particularly effective, while they have been treated for one or two years, the virus is still positive, and the doctor asks to continue the treatment and does not allow to stop the medication. In fact, the effect of treatment will vary from patient to patient with different conditions, and the time to discontinue treatment should not be applied across the board. Clinical data show that patients with more than twice the transaminases and HBVDNA levels less than 9 times 10 are more likely to achieve the discontinuation criteria, and such patients have up to 47% chance of e antigen serological conversion at 2 years if they receive tibivudine treatment, and thus achieve discontinuation. For patients who do not meet these criteria, experienced specialists can use a “roadmap” to adjust treatment regimens in time to improve outcomes. “For example, if a patient’s HBVDNA does not drop below 10,000 copies per milliliter of blood after six months of nucleoside analogs, he or she will need to be followed up more closely and the treatment plan can be adjusted if necessary. ”Hepatitis B antiviral is never a straight path, but as long as we choose the right drugs, choose a scientific program, and stick to it, we can definitely walk a path of hope and eventually achieve drug cessation. Patients must have confidence.